{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0833","upperLimit":"0.0854","value":"0.0837"},{"groupId":"OG001","lowerLimit":"0.0431","upperLimit":"0.319","value":"0.0833"},{"groupId":"OG002","lowerLimit":"0.0417","upperLimit":"0.0847","value":"0.0819"},{"groupId":"OG003","lowerLimit":"0.0417","upperLimit":"0.0875","value":"0.0500"},{"groupId":"OG004","lowerLimit":"0.0403","upperLimit":"0.296","value":"0.0833"},{"groupId":"OG005","lowerLimit":"0.0417","upperLimit":"0.305","value":"0.0840"},{"groupId":"OG006","lowerLimit":"0.0417","upperLimit":"0.285","value":"0.0858"},{"groupId":"OG007","lowerLimit":"0.0417","upperLimit":"0.276","value":"0.0840"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"88"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"22"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0660","upperLimit":"0.170","value":"0.122"},{"groupId":"OG001","lowerLimit":"0.0417","upperLimit":"0.0875","value":"0.0618"},{"groupId":"OG002","lowerLimit":"0.0222","upperLimit":"0.165","value":"0.0417"},{"groupId":"OG003","lowerLimit":"0.0229","upperLimit":"0.0882","value":"0.0833"},{"groupId":"OG004","lowerLimit":"0.0208","upperLimit":"0.278","value":"0.0830"},{"groupId":"OG005","lowerLimit":"0.0208","upperLimit":"1.00","value":"0.0642"},{"groupId":"OG006","lowerLimit":"0.0208","upperLimit":"1.00","value":"0.0854"},{"groupId":"OG007","lowerLimit":"0.0257","upperLimit":"0.172","value":"0.0826"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"40"},{"groupId":"OG005","value":"72"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0438","upperLimit":"0.292","value":"0.0844"},{"groupId":"OG001","lowerLimit":"0.0431","upperLimit":"0.0896","value":"0.0833"},{"groupId":"OG002","lowerLimit":"0.0806","upperLimit":"0.0847","value":"0.0833"},{"groupId":"OG003","lowerLimit":"0.0417","upperLimit":"0.169","value":"0.0500"},{"groupId":"OG004","lowerLimit":"0.0403","upperLimit":"0.294","value":"0.0833"},{"groupId":"OG005","lowerLimit":"0.0403","upperLimit":"0.299","value":"0.0837"},{"groupId":"OG006","lowerLimit":"0.0417","upperLimit":"0.285","value":"0.0840"},{"groupId":"OG007","lowerLimit":"0.0417","upperLimit":"0.271","value":"0.0837"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"41"},{"groupId":"OG005","value":"88"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"22"}],"units":"Participants"}],"title":"total Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0431","upperLimit":"0.0868","value":"0.0649"},{"groupId":"OG001","lowerLimit":"0.0417","upperLimit":"0.0875","value":"0.0618"},{"groupId":"OG002","lowerLimit":"0.0222","upperLimit":"0.0854","value":"0.0417"},{"groupId":"OG003","lowerLimit":"0.0229","upperLimit":"0.159","value":"0.0833"},{"groupId":"OG004","lowerLimit":"0.0208","upperLimit":"0.275","value":"0.0632"},{"groupId":"OG005","lowerLimit":"0","upperLimit":"2.11","value":"0.0639"},{"groupId":"OG006","lowerLimit":"0.0208","upperLimit":"4.00","value":"0.132"},{"groupId":"OG007","lowerLimit":"0.0257","upperLimit":"0.172","value":"0.0858"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"39"},{"groupId":"OG005","value":"72"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"total Ab: Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"0.0833","upperLimit":"0.0833","value":"0.0833"},{"groupId":"OG004","lowerLimit":"0.0458","upperLimit":"0.172","value":"0.0854"},{"groupId":"OG005","lowerLimit":"0.0417","upperLimit":"0.294","value":"0.0844"},{"groupId":"OG006","lowerLimit":"0.0833","upperLimit":"0.285","value":"0.128"},{"groupId":"OG007","lowerLimit":"0.0417","upperLimit":"6.81","value":"0.165"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"28"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"16"}],"units":"Participants"}],"title":"SG3199: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"0.0417","upperLimit":"2.06","value":"1.05"},{"groupId":"OG004","lowerLimit":"0.0840","upperLimit":"0.153","value":"0.120"},{"groupId":"OG005","lowerLimit":"0.0222","upperLimit":"13.8","value":"0.0632"},{"groupId":"OG006","lowerLimit":"0.0299","upperLimit":"0.992","value":"0.165"},{"groupId":"OG007","lowerLimit":"0.0833","upperLimit":"0.280","value":"0.162"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"title":"SG3199: Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"88"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"22"}],"units":"Participants"}],"description":"Tmax for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).\n\nResults for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.","dispersionType":"Full Range","groups":[{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG000","title":"Part 1: 15 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG001","title":"Part 1: 30 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG002","title":"Part 1: 60 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG003","title":"Part 1: 90 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG004","title":"Parts 1 and 2: 120 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG005","title":"Parts 1 and 2: 150 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG006","title":"Part 1: 200 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG007","title":"Part 1: 200 μg/kg Q6W"}],"paramType":"MEDIAN","populationDescription":"Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.","reportingStatus":"POSTED","timeFrame":"Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)","title":"Time to Reach the Maximum Serum Concentration (Tmax) for ADCT-402","type":"SECONDARY","unitOfMeasure":"days"}